Pharma Market Forecasts
Always three numbers, never one.
A defensible approach to pharma market forecasting — base, upside and downside scenarios with explicit driver assumptions — for strategy, BD and investor decisions.
"What is the credible forecast range — and what assumptions move the answer?"
Single-point forecasts are decision theatre. Defensible forecasts are scenario-based with explicit driver assumptions and transparent sensitivities.
Pharma market forecasting is decision theatre when delivered as a single number. Done right, it’s a driver-decomposed scenario range with transparent sensitivities — exactly what strategy and IC committees need.
What we’re seeing in the data.
Drivers are more useful than outputs
Decision teams care about what changes the answer.
Sensitivity analysis is the deliverable
Tornado charts beat single-line forecasts.
Scenario range usually 30–60%
Across base / upside / downside in pharma forecasts.
Pipeline assumption is the biggest driver
Pipeline launch list dominates forecast variance.
How to think about it.
-
01
Define driver tree
Volume, pricing, mix, LoE, pipeline, access.
-
02
Build base case
Most-likely values per driver.
-
03
Define upside / downside
Plausible alternate driver values.
-
04
Run sensitivity analysis
Tornado chart of driver impact.
-
05
Communicate as ranges
Bands with explicit assumptions.
What separates a good answer from a defensible one.
Pharma forecasts have inherent ±20% noise.
Trial data shifts forecast more than time.
EU HTA outcomes drive global price erosion.
Trial-grade efficacy ≠ launch share.
Where the signal comes from.
Common questions.
How many scenarios is right?
Three is the practical sweet spot. More confuses; fewer hides risk.
How wide is a typical range?
30–60% across base / upside / downside is normal in pharma.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist